Does SORT1-region rs599839 AA lead to less favorable hepatic ApoB handling?

The chromosome 1p13.3 locus is one of the most strongly validated genetic determinants of cardiovascular risk, acting primarily through the modulation of hepatic lipid metabolism.

Mechanistic pathways of hepatic ApoB handling

• Cis-Regulatory Downregulation: The rs599839 AA genotype functions as a powerful cis-regulatory modifier that significantly reduces the hepatic expression of SORT1, the gene encoding sortilin.
• Impaired Lysosomal Routing: Sortilin normally serves as a critical sorting receptor in hepatocytes, capturing intracellular apolipoprotein B-100 (ApoB-100) and trafficking it to lysosomes for autophagic degradation, particularly during states of metabolic or endoplasmic reticulum stress.
• Secretory Escape: Under the rs599839 AA genotype, diminished sortilin levels allow nascent ApoB to bypass this pre-secretory quality control pathway, facilitating its assembly into very-low-density lipoproteins (VLDL) and accelerating hepatic export.

Clinical lipid implications

• Elevated Atherogenic Lipoproteins: This shift in intracellular trafficking directly alters circulating lipid metrics, as the hypersecretion of VLDL raises systemic concentrations of its downstream metabolic remnants.
• Adverse Lipid Panels: Consequently, carriers of the AA genotype exhibit higher circulating levels of ApoB, low-density lipoprotein particle number (LDL-P), LDL cholesterol (LDL-C), and non-HDL-C compared to carriers of the protective G allele, who exhibit robust sortilin expression and efficient lipoprotein clearance.

Bottom line

• The rs599839 AA genotype downregulates hepatic sortilin, impairing the lysosomal degradation of ApoB-100 and driving the hypersecretion of atherogenic VLDL and LDL particles.